140 related articles for article (PubMed ID: 38228122)
1. Therapy with hypomethlyating agents/venetoclax in patients with newly diagnosed acute myeloid leukaemia requiring admission to the intensive care unit: Possible reduction in side effects with preserved efficacy.
Fiedler W
Br J Haematol; 2024 Apr; 204(4):1135-1136. PubMed ID: 38228122
[TBL] [Abstract][Full Text] [Related]
2. The heart of VIALE-A: Cardiac complications of hypomethylating agents and venetoclax in acute myeloid leukaemia.
Patel SA
Br J Haematol; 2024 Apr; 204(4):1137-1138. PubMed ID: 38339780
[TBL] [Abstract][Full Text] [Related]
3. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
4. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study.
Bazinet A; Garcia-Manero G; Short N; Alvarado Y; Bataller A; Abuasab T; Islam R; Montalbano K; Issa G; Maiti A; Yilmaz M; Jain N; Masarova L; Kornblau S; Jabbour E; Montalban-Bravo G; Rausch CR; Pierce S; DiNardo CD; Kadia T; Daver N; Konopleva M; Huang X; Kantarjian H; Ravandi F
Lancet Haematol; 2024 Apr; 11(4):e276-e286. PubMed ID: 38452788
[TBL] [Abstract][Full Text] [Related]
5. Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukaemia.
Liang P; Xie Y; Liu Z; Wang D; Li Q; Lu Y; Xue S; Wang Y; Chen S; Wu D; Fu J
Br J Haematol; 2024 Apr; 204(4):1219-1226. PubMed ID: 38180132
[TBL] [Abstract][Full Text] [Related]
6. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
7. Choosing between intensive and less intensive front-line treatment approaches for older patients with newly diagnosed acute myeloid leukaemia.
Short NJ; Kantarjian H
Lancet Haematol; 2022 Jul; 9(7):e535-e545. PubMed ID: 35772432
[TBL] [Abstract][Full Text] [Related]
8. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
Agarwal S; Gopalakrishnan S; Mensing S; Potluri J; Hayslip J; Kirschbrown W; Friedel A; Menon R; Salem AH
Hematol Oncol; 2019 Oct; 37(4):464-473. PubMed ID: 31251400
[TBL] [Abstract][Full Text] [Related]
9. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.
Kadia TM; Reville PK; Borthakur G; Yilmaz M; Kornblau S; Alvarado Y; Dinardo CD; Daver N; Jain N; Pemmaraju N; Short N; Wang SA; Tidwell RSS; Islam R; Konopleva M; Garcia-Manero G; Ravandi F; Kantarjian HM
Lancet Haematol; 2021 Aug; 8(8):e552-e561. PubMed ID: 34329576
[TBL] [Abstract][Full Text] [Related]
10. Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents.
Johnson IM; Karrar O; Rana M; Iftikhar M; Chen S; McCullough K; Saliba AN; Al-Kali A; Alkhateeb H; Begna K; Litzow M; Hogan WJ; Shah M; Patnaik MM; Pardanani A; Hermann J; Tefferi A; Gangat N
Br J Haematol; 2024 Apr; 204(4):1232-1237. PubMed ID: 38311378
[TBL] [Abstract][Full Text] [Related]
11. AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia.
Todisco E; Papayannidis C; Fracchiolla N; Petracci E; Zingaretti C; Vetro C; Martelli MP; Zappasodi P; Di Renzo N; Gallo S; Audisio E; Griguolo D; Cerchione C; Selleri C; Mattei D; Bernardi M; Fumagalli M; Rizzuto G; Facchini L; Basilico CM; Manfra I; Borlenghi E; Cairoli R; Salutari P; Gottardi M; Molteni A; Martini V; Lunghi M; Fianchi L; Cilloni D; Lanza F; Abruzzese E; Cascavilla N; Rivellini F; Ferrara F; Maurillo L; Nanni J; Romano A; Cardinali V; Gigli F; Roncoroni E; Federico V; Marconi G; Volpi R; Sciumè M; Tarella C; Rossi G; Martinelli G;
Cancer; 2023 Apr; 129(7):992-1004. PubMed ID: 36692409
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy.
Chua CC; Roberts AW; Reynolds J; Fong CY; Ting SB; Salmon JM; MacRaild S; Ivey A; Tiong IS; Fleming S; Brown FC; Loo S; Majewski IJ; Bohlander SK; Wei AH
J Clin Oncol; 2020 Oct; 38(30):3506-3517. PubMed ID: 32687450
[TBL] [Abstract][Full Text] [Related]
13. How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia.
Maiti A; Konopleva MY
Cancer J; 2022 Jan-Feb 01; 28(1):2-13. PubMed ID: 35072368
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study.
Karol SE; Alexander TB; Budhraja A; Pounds SB; Canavera K; Wang L; Wolf J; Klco JM; Mead PE; Das Gupta S; Kim SY; Salem AH; Palenski T; Lacayo NJ; Pui CH; Opferman JT; Rubnitz JE
Lancet Oncol; 2020 Apr; 21(4):551-560. PubMed ID: 32171069
[TBL] [Abstract][Full Text] [Related]
15. Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia.
Salhotra A; Tsai NC; Zhang J; Ngo D; Aribi A; Sandhu K; Ball B; Al-Malki M; Ali H; Koller P; Artz A; Forman S; Nakamura R; Stein A; Marcucci G; Aldoss I; Pullarkat V
Br J Haematol; 2022 Mar; 196(6):e71-e74. PubMed ID: 34931310
[No Abstract] [Full Text] [Related]
16. Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial.
Wang H; Mao L; Yang M; Qian P; Lu H; Tong H; Xie W; Zhou D; Huang X; Wang Y; Xu G; Lu Y; Wei J; Mai W; Ye X; Meng H; Shen Y; Huang J; Yu W; Sun J; Sheng J; Yan X; Jin J; Zhu HH
Lancet Haematol; 2022 Jun; 9(6):e415-e424. PubMed ID: 35512726
[TBL] [Abstract][Full Text] [Related]
17. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study.
Lachowiez CA; Reville PK; Kantarjian H; Jabbour E; Borthakur G; Daver N; Loghavi S; Furudate K; Xiao L; Pierce S; Short NJ; Maiti A; Yilmaz M; Sasaki K; Takahashi K; Konopleva M; Pemmaraju N; Popat U; Shpall E; Garcia-Manero G; Ravandi F; DiNardo CD; Kadia TM
Lancet Haematol; 2022 May; 9(5):e350-e360. PubMed ID: 35483396
[TBL] [Abstract][Full Text] [Related]
18. Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia.
Othman TA; Azenkot T; Moskoff BN; Tenold ME; Jonas BA
Future Oncol; 2021 Aug; 17(23):2989-3005. PubMed ID: 34024158
[TBL] [Abstract][Full Text] [Related]
19. Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases.
Wang N; He J; Liu F
Chemotherapy; 2022; 67(3):178-182. PubMed ID: 35306492
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival.
Karrar O; Abdelmagid M; Rana M; Iftikhar M; McCullough K; Al-Kali A; Alkhateeb HB; Begna KH; Elliott MA; Mangaonkar A; Saliba A; Hefazi Torghabeh M; Litzow MR; Hogan W; Shah M; Patnaik MM; Pardanani A; Badar T; Murthy H; Foran J; Palmer J; Sproat L; Khera N; Arana Yi C; Tefferi A; Gangat N
Am J Hematol; 2024 Feb; 99(2):E63-E66. PubMed ID: 38100217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
